Pharma Equity Group A/S (CPH:PEG)

Market Cap	114.65M -20.8%
Revenue (ttm)	n/a
Net Income	-25.38M
EPS	-0.02
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,907
Open	0.0934
Previous Close	0.0842
Day's Range	0.0934 - 0.0934
52-Week Range	0.0602 - 0.1500
Beta	1.00
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of color...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 5
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 28, 2026

Data Sources Report a data error